Review Article
Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Table 5
Changes in metabolic parameters in the Swiss SWITCH-EE trial and the Spanish ETRA-SWITCH trial.
| (a) Swiss SWITCH-EE trial: changes in lipids six weeks after switching from efavirenz to etravirine treatment (mmol/L) |
| Lab parameter
Median (IQ range) | End of efavirenz phase | End of etravirine phase | Change between EFV and ETR phases |
| | ALT | 33.0 (24–55.5) | 37.0 (26–64) | 0.0 (−5.5, 6.0) | | Total cholesterol | 5.5 (4.7–6.3) | 4.6 (3.9–5.5) | −0.7 (−1.1, −0.2) | | HDL cholesterol | 1.1 (0.9–1.4) | 1.1 (0.9–1.3) | −0.02 (−0.1, +0.1) | | LDL cholesterol | 3.3 (2.6–3.8) | 2.8 (2.1–3.3) | −0.6 (−0.7, −0.1) | | Triglycerides | 1.7 (1.2–2.4) | 1.4 (1.0–1.9) | −0.3 (−0.9, −0.1) |
|
|
| (b) ETRA-SWITCH trial: changes in lipids from baseline, to Week 24 (mmol/L) |
| | Mean lipid levels (95% C.I) | Etravirine group | PI control group | | Baseline | Week 24 | Baseline | Week 24 |
| | Total cholesterol | 5.33 (4.48–6.31) | 4.81 (4.14–5.64) | 4.82 (4.30–5.70) | 5.39 (4.51–6.01) | | HDL-cholesterol | 1.35 (1.01–1.66) | 1.24 (0.88–1.61) | 1.30 (1.04–1.58) | 1.24 (1.01–1.37) | | LDL cholesterol | 2.85 (2.41–3.83) | 3.13 (2.36–3.52) | 2.98 (2.43–3.52) | 2.77 (2.20–3.68) | | Triglycerides | 1.89 (1.20–2.60) | 1.21 (0.90–1.50) | 1.20 (0.80–2.01) | 1.40 (0.85–2.73) |
|
|
, comparison between treatments; IQ range: interquartile range; ETR: etravirine; EFV: efavirenz.
|
